Ask a generalist investor what a device does and the executive summary usually answers it. Ask a specialist MedTech investor the same question, and they open the technical file because the answer determines the capital required, the timeline to market, and the evidence the company still needs to produce. A data room built around a capitalisation table, a profit and loss statement, and a handful of signed contracts answers the financial questions well. It rarely answers the four that decide whether a MedTech round happens at all.
European MedTech investors have made those four questions explicit rather than implicit. Seed-stage diligence in this sector routinely includes a regulatory pathway review, a classification rationale check, a review of the clinical evaluation strategy, and an assessment of who on the team can own regulatory and quality responsibilities once the company operates under a certified system. By Series A, the round is almost always tied to a specific regulatory or clinical milestone: a CE mark approaching, key clinical evidence complete, first commercial letters of intent signed, a reimbursement pathway identified.
1. What exactly is the device?
The starting point is the intended purpose and the risk classification, not the pitch. Under the EU Medical Device Regulation, classification follows the rules set out in Annex VIII, and software that meets the definition of a medical device is classified under the same logic as any physical device. In the United States, the equivalent question is which pathway applies: 510(k), De Novo, or PMA. Two founders with a similar product can face very different capital needs depending on which answer is correct. A data room that states the classification without the reasoning behind it is asking the investor to redo that work.
2. What evidence and is it proportionate?
Clinical evaluation under the MDR, governed by Article 61, has to match the device’s classification and its stated intended purpose. Pilot data collected to demonstrate one claim doesn’t automatically support a clinical evaluation built for a different one. Specialist investors distinguish carefully between evidence that demonstrates safety and performance and evidence that only demonstrates that a demo works. The gap between the two is one of the more common reasons a seed round takes longer than founders expect, and it shows up in diligence long before it shows up in a term sheet.
3. Who pays?
Reimbursement is not a step that happens after the raise. It’s part of the business model and payers increasingly ask for the same kind of comparative evidence that regulators do. Germany’s DiGA pathway runs a structured review at BfArM and requires comparative clinical data showing a positive care effect before a device earns a permanent listing, after an initial period on provisional terms. France’s PECAN pathway follows the same logic: provisional reimbursement for up to twelve months while the manufacturer gathers the clinical benefit evidence a permanent listing will require. In the United Kingdom, NICE’s Evidence Standards Framework sets tiered evidence requirements according to the device’s risk and the claim being made.
Engineering quality alone doesn’t settle a reimbursement decision. Payers reimburse a device because a defined population is shown to benefit, under a standard of proof set in advance.
4. What does the runway actually cost?
None of this is free, and it’s rarely fast. Investors who specialise in this sector are direct about the consequence: getting the regulatory or commercial strategy wrong can add years and tens of millions of euros before a company reaches an exit or a major value inflection point. It belongs in the financial model, tied to the same milestones regulators and payers use. A valuation that can’t be defended against those milestones won’t survive diligence.
5. Rules that are still moving
Two frameworks that matter to MedTech founders are currently in motion, and a data room should show that the company knows which one applies to it and why, rather than reciting a calendar that may change. The European Commission has proposed a targeted revision of the MDR and the IVDR, intended to reduce administrative burden without lowering safety requirements. The proposal was submitted to the European Parliament and the Council in December 2025 and is not yet adopted. Separately, the EU’s Digital Omnibus on AI, now in force, has pushed back the date at which high-risk obligations apply to AI embedded in regulated products, including medical devices, to 2 August 2028. The device’s existing MDR or IVDR obligations are unaffected by that change and run on a separate timeline. A device with an embedded AI component now answers to two regimes on two different clocks, and the data room should be explicit about which clock governs which claim.
6. Where a token fits and where it doesn’t
Tokenised structures are rarely the right answer in regulated MedTech financing, and a data room should say so plainly rather than avoid the subject. The one case where a token has a genuine operating rationale is narrow: a network that needs to coordinate access across multiple research or clinical sites, where the token’s function is to govern that access rather than to raise money. In that case, the instrument tracks the network’s real activity, a site coming online, a data set becoming available, a study phase closing, not a financing schedule invented for the round. Outside that kind of network, a token adds a second instrument for the investor to diligence without adding a function the business actually needs, and the honest answer is to leave it out.
A data room should make the case that the round is timed correctly and priced defensibly. The founders who move through specialist diligence quickly are usually the ones who answered these four questions before the investor had to ask them.
Frequently asked
What do MedTech investors look for beyond the financials?
European MedTech seed diligence typically includes a regulatory pathway review, a classification rationale check, and a review of the clinical evaluation strategy under the MDR, alongside an assessment of who on the team owns regulatory and quality responsibility. By Series A, the round is usually tied to a specific regulatory or clinical milestone.
When should reimbursement enter the fundraising plan?
From the start. Pathways such as Germany’s DiGA and France’s PECAN grant provisional reimbursement while the manufacturer gathers the comparative clinical evidence a permanent listing requires, and the UK’s NICE Evidence Standards Framework sets tiered evidence requirements by risk. Investors expect the reimbursement strategy to already be part of the model.
Does the AI Act change what a MedTech data room needs?
For a device with an embedded AI component, yes, on a separate timeline. The EU’s Digital Omnibus on AI has pushed the date at which high-risk obligations apply to AI in regulated products, medical devices included, to 2 August 2028. The device’s MDR or IVDR obligations are unchanged and run on their own clock.
Sources and references
- European Commission, proposal for a targeted revision of the Medical Device Regulation and the In Vitro Diagnostic Regulation, submitted to the European Parliament and the Council, December 2025.
- Regulation (EU) 2017/745 (MDR): Article 61 on clinical evaluation and Annex VIII on classification rules.
- Regulation (EU) 2026/1744, the Digital Omnibus on AI, in force from July 2026: high-risk obligations for AI embedded in Annex I products, medical devices included, postponed to 2 August 2028.
- Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM): DiGA Fast-Track evaluation procedure, Germany.
- Haute Autorité de Santé (HAS): Prise en Charge Anticipée Numérique (PECAN) framework, France.
- National Institute for Health and Care Excellence (NICE): Evidence Standards Framework for digital health technologies, United Kingdom.
- Stifel Venture Banking, Navigating the New MedTech Playbook, on widening seed-to-Series A diligence in MedTech, 2026.
- AYAKO Partners internal analysis.